Stay updated on Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to reflect the submission of results and has been revised to version 2.15.2, replacing the previous version 2.15.0.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and criteria for a clinical trial on Stage IV pancreatic cancer, while retaining key collaborators and the study's version number.SummaryDifference33%
- Check44 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 6, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.6%
- Check80 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check102 days agoChange DetectedThe page has been updated to reflect the ongoing study of nivolumab, cabiralizumab, and gemcitabine in patients with stage IV pancreatic cancer, including new dates and details about the trial's purpose and outcomes. Some previous information has been removed, indicating a shift in focus or status of the study.SummaryDifference14%
- Check109 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.